This trial is testing if a medication can help improve the success rate of surgery for people with a certain eye condition.
- Proliferative Vitreoretinopathy
- Retinal Detachment With Multiple Breaks, Unspecified Eye
1 Primary · 5 Secondary · Reporting Duration: 4 months
Awards & Highlights
2 Treatment Groups
Intervention (serial IAI)
1 of 2
1 of 2
150 Total Participants · 2 Treatment Groups
Primary Treatment: Intravitreal aflibercept injection · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent is the participant enrollment for this trial?
"Affirmative. Records hosted on clinicaltrials.gov supply evidence that this research project, first posted on October 15th 2020, is currently seeking participants. Approximately 150 people will be enrolled from a single trial site." - Anonymous Online Contributor
What conditions typically respond to Intravitreal aflibercept injection?
"Intravitreal aflibercept injection is both an effective and safe treatment for wet age-related [macular degeneration](https://www.withpower.com/clinical-tri[als](https://www.withpower.com/clinical-trials/als)/macular-degeneration) (wAMD). It has also been employed to alleviate associated conditions such as diabetic macular edema, retinal vein occlusion, and choroidal neovascularization." - Anonymous Online Contributor
Is it possible to still join this research endeavor?
"According to the data on clinicaltrials.gov, this medical research is actively searching for participants. The trial was published in October 2020 and amended in May 2022." - Anonymous Online Contributor
To what extent can intravitreal aflibercept injection pose a risk for patients?
"Our assessment of intravitreal aflibercept injection's safety is rated 2, indicating that while clinical evidence exists to back its security there are no studies attesting to its efficacy." - Anonymous Online Contributor